Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Long-term treatment with lumasiran: final results from the phase 2 open-label extension study

Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

Development of an X-ray-Based Bone Oxalosis Grading Scale to Access Oxalate Accumulation in Patients with Primary Hyperoxaluria Type 1

The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease

ATTR Amyloidosis Disease State Handout

This handout provides an overview of ATTR amyloidosis manifestations and the diagnostic tools that can be used to assess their presentation.

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Screening, Recognition, and Barriers to Diagnosis of ATTR

This deck highlights the screening, recognition, and barriers of diagnosis in ATTR.

Real-World Persistency on Tafamidis: An Analysis of US Insurance Claims Data

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results

Symptoms and Disease Burden of ATTR

This slide deck provides an overview of the symptoms and disease burden of ATTR.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.